TRITANIUM PERI-APATITIE ACETABULAR SOLID-BACKED SHELL, TRITANIUM PERI-APATITE

K101072 · Howmedica Osteonics Corp. · LPH · Apr 11, 2011 · Orthopedic

Device Facts

• Record ID: K101072
• Device Name: TRITANIUM PERI-APATITIE ACETABULAR SOLID-BACKED SHELL, TRITANIUM PERI-APATITE
• Applicant: Howmedica Osteonics Corp.
• Product Code: LPH · Orthopedic
• Decision Date: Apr 11, 2011
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3358
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Tritanium® Peri-Apatite™ Acetabular Shell is a sterile, single-use device intended for use in primary and revision total hip arthroplasty to alleviate pain and restore function.

Device Story

Tritanium® Peri-Apatite™ Acetabular Shell System is a hemispherical, metallic acetabular shell for cementless, biologic fixation in total hip arthroplasty. Device features a Ti-6Al-4V alloy shell with a Tritanium® (CPTi) Particle Sintered Foam (PSF) coating and an overlying Peri-Apatite (precipitated calcium phosphate) coating. Available in solid-backed or cluster screw-hole designs; optional dome hole plugs seal the shell. Compatible with polyethylene Trident® inserts, constrained liners, and modular dual mobility (MDM) liners. Used by orthopedic surgeons in clinical settings for primary or revision hip replacement. Provides a stable acetabular component to restore joint function and alleviate pain. Device is single-use.

Clinical Evidence

No clinical data provided. Substantial equivalence based on non-clinical laboratory testing, including mechanical bond strength, fatigue testing, and coating characterization.

Technological Characteristics

Acetabular shell forged from Ti-6Al-4V alloy (ASTM F136). Tritanium® coating (CPTi) per ASTM F1580. Peri-Apatite™ coating (precipitated calcium phosphate) per ASTM F-1609. Hemispherical form factor, 44-72 mm OD. Cementless, porous-coated design. Single-use. No software or electronic components.

Indications for Use

Indicated for patients with painful, disabling hip joint disease (non-inflammatory degenerative arthritis, rheumatoid arthritis, post-traumatic arthritis, late stage avascular necrosis), revision of failed previous hip procedures, clinical management problems where alternative techniques are less likely to succeed, or poor bone stock/acetabular deficiencies. Constrained liners indicated for high dislocation risk (prior dislocation, bone loss, laxity, neuromuscular disease, instability). Modular dual mobility (MDM) liners indicated for noninflammatory degenerative joint disease, rheumatoid arthritis, functional deformity, revision, nonunion/fractures of proximal femur, and dislocation risks. Cementless use only.

Regulatory Classification

Identification

A hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis is a device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across the joint. This generic type of device has a femoral component made of a cobalt-chromium-molybdenum (Co-Cr-Mo) alloy or a titanium-aluminum-vanadium (Ti-6Al-4V) alloy and an acetabular component composed of an ultra-high molecular weight polyethylene articulating bearing surface fixed in a metal shell made of Co-Cr-Mo or Ti-6Al-4V. The femoral stem and acetabular shell have a porous coating made of, in the case of Co-Cr-Mo substrates, beads of the same alloy, and in the case of Ti-6Al-4V substrates, fibers of commercially pure titanium or Ti-6Al-4V alloy. The porous coating has a volume porosity between 30 and 70 percent, an average pore size between 100 and 1,000 microns, interconnecting porosity, and a porous coating thickness between 500 and 1,500 microns. The generic type of device has a design to achieve biological fixation to bone without the use of bone cement.

Predicate Devices

• Howmedica Osteonics Tritanium Acetabular Shell System (K081171)
• Howmedica Osteonics Vitalock Solid Back Acetabular Shell with Peri-Apatite (K971206)
• Landos Inc. Corail Stem (K953111)
• Aesculap BiContact Hip System with u-CaP (K043079)
• Smith & Nephew Hip Systems with HA Coating (K090982)

Submission Summary (Full Text)

{0}------------------------------------------------

APR 1 1 2011

#### 510(k) Summary

Howmedica Osteonics Corp. 325 Corporate Drive Mahwah. NJ 07430

K101072 p1/3

Contact Person

Sponsor

Karen Ariemma Project Manager, Regulatory Affairs/Regulatory Compliance Howmedica Osteonics Corp. 325 Corporate Drive Mahwah, NJ 07430 Phone: [phone]

Date Prepared: April 8, 2011

Tritanium® Peri-Apatite™ Acetabular Shell System Proprietary Name:

Artificial Hip Replacement Components - Acetabular Common Name:

#### Classification Name:

21 CFR §888.3358: Hip joint metal/polymer/metal semi-constrained and porous-coated uncemented prosthesis

21 CFR §888.3310: Hip joint metal/polymer constrained cemented or uncemented prosthesis.

21 CFR §888.3353: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis:

21 CFR §888.3360 - Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis.

21 CFR §888.3350 - Hip joint metal/polymer semi-constrained cemented prosthesis

LPH, MEH, LZO, KWZ, LWJ and JDI Product Codes:

Legally Marketed Device to Which Substantial Equivalence is Claimed: Howmedica Osteonics Tritanium Acetabular Shell System: K081171 Howmedica Osteonics Vitalock Solid Back Acetabular Shell with Peri-Apatite: K971206 Landos Inc. Corail Stem: K953111 Aesculap BiContact Hip System with u-CaP K043079 Smith& Nephew, Smith & Nephew Hip Systems with HA Coating: K090982.

Device Description: The Tritanium® Peri-Apatite ™ acetabular shells are available in both solid backed and cluster screw-hole designs for cementless, biologic fixation. The Howmedica Osteonics Tritanium® Peri-Apatite™ Acetabular Shell consists of a hemispherical, metallic acetabular shell with a Tritanium® (CPTi) coating referred to as a Particle Sintered Foam (PSF) coating with an overlying Peri-Apatite coating (precipitated calcium phosphate coating). The Peri-Apating process is identical to that cleared in K971206 but to a greater thickness range of 35-75 microns. The Tritanium® CPTi PSF coating originally manufactured from material conforming to ASTM F67 was modified to conform to ASTM F1580. The dual coating (Peri-Apatite™ overlying the PSF coating) at

{1}------------------------------------------------

K101072 p 2/3

the thickest specification met the definition of a porous coating per 21 CFR 888.3358 with no additional claims over biologic fixation. The dome hole plugs are optional devices which are available to seal the Howmedica Osteonics Tritanium® Acetabular Shells. The plugs are to be threaded into the dome holes of the shell.

The shells will be available in sizes 44-72 mm outside diameter (OD) in 2 mm increments. The acetabular shells are forged from Ti-6Al-4V alloy per ASTM F136; the Tritanium® coating is fabricated from Commercially Pure Titanium per ASTM F1580; and the Peri-Apatite™ coating is a precipitated calcium phosphate coating per ASTM F-1609.

The Tritanium® Peri-Apatite™ Acetabular Shells are compatible with polyethylene Trident® inserts, constrained liners and modular dual mobility liners. The subject shells have an identical insert locking mechanism to that employed with compatible Tritanium acetabular shell system predicates. All shells are single use devices. The outer surface of the acetabular shell has the identical geometry as the predicate Tritanium® Acetabular Shell System determined substantially equivalent via 510(k) K081171.

Intended Use: The Tritanium® Peri-Apatite™ Acetabular Shell is a sterile, single-use device intended for use in primary and revision total hip arthroplasty to alleviate pain and restore function.

## Indications:

The indications for use of the total hip replacement prostheses include:

- 1. Painful, disabling joint disease of the hip resulting from: non-inflammatory degenerative arthritis, rheumatoid arthritis, post-traumatic arthritis, or late stage avascular necrosis.
- Revision of previous failed femoral head replacement, shell arthroplasty or other procedure. 2.
- Clinical management problems where arthrodesis or alternative reconstructive techniques are 3. less likely to achieve satisfactory results.
- Where bone stock is of poor bone quality or inadequate for other reconstructive techniques as 4. indicated by deficiencies of the acetabulum.

Additional indications for use when using constrained liners: The device is indicated for use as a component of a total hip prosthesis in primary and revision patients at high risk of hip dislocation due to a history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease, or intraoperative instability.

Additional indications for use when using modular dual mobility (MDM) liners: The device is indicated for use as a component of a total hip prosthesis and include:

- 1. Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis;
- 2. Rheumatoid arthritis;
- Correction of functional deformity; 3.
- Revision procedures where other treatments or devices have failed; 4.
- Treatment of nonunion, femoral neck and trochanteric fractures of the proximal femur with న్. head involvement that are unmanageable using other techniques; and
- 6. Dislocation risks

The MDM liners are intended for cementless use only. The acetabular shell is intended for cementless use only.

{2}------------------------------------------------

K101072
r3/3

Summary of Technologies: The technology characteristics are the same basic principles as the predicates with minor differences occurring in the material of Tritanium underlying surface and the Peri-Apatite thickness.

Non-Clinical Testing: Non-clinical laboratory testing was performed to determine substantial equivalence. Non-clinical testing was provided as outlined in the FDA Guidance Document entitled "Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone or Bone Cement (28 April 1994)" for the underlying Tritanium surface which included additional testing on the CPT Tritanium conforming to ASTM F1580 in terms of static tensile, static shear and shear fatigue bond strength testing. The dual coating/surface was characterized per the FDA Guidance document entitled "510(k) Information Needed for Hydroxyapatite Coated Orthopaedic Implants (February 20, 1997)." All characterization parameters on the final dual coating/surface were provided. The NIST SRM 2910(a) material was used as a comparator for the Xray diffraction, dissolution rate and solubility product parameters. The dual coating/surface underwent additional characterization to demonstrate that the definition of porosity was met per 21 CFR 888.3358 at the thickest specification. Additionally, four-point bend fatiguing, abrasion, and fatigue strength of the subject acetabular shell were performed. Third body wear information was provided to address the theoretical risk. All of the observed results indicate that the subject Tritanium® Peri-Apatite™ Acetabular Shell System is substantially equivalent to devices currently cleared for marketing.

Clinical Testing: None provided as a basis for substantial equivalence.

Conclusion: The Tritanium® Peri-Apatite™ Acetabular Shell System is substantially equivalent to the predicate devices identified in this premarket notification.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal features the department's name encircling a stylized eagle-like symbol. The symbol is composed of three angled lines that form the body and wings of the bird, with three curved lines below representing its legs or feet.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

Howmedica Osteonics Corp. % Ms. Karen Ariemma, RAC Project Manager, Regulatory Affairs/ Regulatory Compliance 325 Corporate Drive Mahwah, New Jersey 07430

APR 1 1 2011

Re: K101072

Trade/Device Name: Tritanium® Peri-Apatite™ Acetabular Shell System (Tritanium® Peri-Apatite™ Acetabular Solid-backed Shell and Tritanium® Peri-Apatite™ Acetabular Cluster Screw-hole Shell) Regulation Number: 21 CFR 888.3358 Regulation Name: Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis Regulatory Class: Class II Product Code: LPH, MEH, LZO, KWZ, LWJ, JDI Dated: March 31, 2011 Received: April 04, 2011

Dear Ms. Ariemma:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{4}------------------------------------------------

Page 2 - Ms. Karen Ariemma, RAC

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Mark N. Melkerson

Mark N. Melkerson Director Division of Surgical, Orthopedic, and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

## Indications for Use

# 510(k) Number (if known): K101072

### Device Name: Tritanium® Peri-Apatite™ Acetabular Shell System

Indications for Use:

The indications for use of the total hip replacement prostheses include:

- Painful, disabling joint disease of the hip resulting from: non-inflammatory degenerative arthritis, ﺘﺴ rheumatoid arthritis, post-traumatic arthritis, or late stage avascular necrosis.
- Revision of previous failed femoral head replacement, shell arthroplasty or other procedure. 2.
- Clinical management problems where arthrodesis or alternative reconstructive techniques are less 3. likely to achieve satisfactory results.
- Where bone stock is of poor bone quality or inadequate for other reconstructive techniques as 4. indicated by deficiencies of the acetabulum.

Additional indications for use when using constrained liners: The device is indicated for use as a component of a total hip prosthesis in primary and revision patients at high risk of hip dislocation due to a history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease, or intraoperative instability.

Additional indications for use when using modular dual mobility (MDM) liners: The device is indicated for use as a component of a total hip prosthesis and include:

- Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis; 1.
- Rheumatoid arthritis; 2.
- Correction of functional deformity; 3.
- Revision procedures where other treatments or devices have failed; 4.
- Treatment of nonunion, femoral neck and trochanteric fractures of the proximal femur with న్.
- head involvement that are unmanageable using other techniques; and
- Dislocation risks 6.

The MDM liners are intended for cementless use only. The acetabular shell is intended for cementless use only.

Over-The-Counter Use Prescription Use . X AND/OR (21 CFR 807 Subpart C) (Part 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

# Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1

(Division Sign-Off)

Division of Surgical, Orthopedic, and Restorative Devices

510(k) Number K101072